6 completed, 2 terminated, 1 not yet recruiting, 1 recruiting. 11 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 6, Terminated 2, Not yet recruiting 1, Recruiting 1, Unknown 1 |
| Phase 1 | 4 | Completed 2, Recruiting 1, Unknown 1 |
Follow TH 302: new trials by email Literature Review of TH 302 trials Research Report on TH 302
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer Evofosfamide - Castration Resistant Prostate Cancer | Phase 2 | Not yet recruiting | University Health Network, Toronto | 35 | 2026-10-01 | 2026-09-24 |
| A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab Evofosfamide, Zalifrelimab, Balstilimab - Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | ImmunoGenesis | 71 | 2025-01-08 | 2025-01-21 |
| A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours TH-302 + Sunitinib - Neuroendocrine Tumors, Pancreatic Neoplasms | Phase 2 | Completed | Grupo Espanol de Tumores Neuroendocrinos | 17 | 2015-05-11 | 2020-07-27 |
| TH-302 in Combination With Bevacizumab for Glioblastoma Bevacizumab, TH-302 - Glioblastoma | Phase 2 | Completed | The University of Texas Health Science Center at San Antonio | 35 | 2015-05-01 | 2020-04-10 |
| A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma TH-302, Doxorubicin - Soft Tissue Sarcoma | Phase 2 | Terminated | Merck KGaA, Darmstadt, Germany | 6 | 2014-12-10 | 2018-12-14 |
| A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma TH-302 - Metastatic Melanoma | Phase 2 | Terminated | ImmunoGenesis | 11 | 2013-05-01 | 2025-05-11 |
| Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma TH-302, TH-302 and Dexamethasone, TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Threshold Pharmaceuticals | 98 | 2012-02-01 | 2016-06-02 |
| Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab TH-302 preoperative, Placebo, TH-302 (escalating) with bevacizumab 10mg/kg - HIGH GRADE GLIOMA | Phase 2 | Completed | The University of Texas Health Science Center at San Antonio | 28 | 2011-06-01 | 2019-07-24 |
| Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma Gemzar (Gemcitabine), TH-302 - Pancreatic Adenocarcinoma | Phase 2 | Completed | ImmunoGenesis | 214 | 2010-06-01 | 2025-05-11 |
| Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors TH-302 - Non-Small Cell Lung Cancer, Prostate Cancer | Phase 1 / Phase 2 | Completed | Threshold Pharmaceuticals | 71 | 2008-08-01 | 2015-05-07 |
| Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma TH-302 - Soft Tissue Sarcoma | Phase 1 / Phase 2 | Completed | ImmunoGenesis | 107 | 2008-08-01 | 2025-05-13 |
Pancreatic Neoplasms (3) · Hypoxia (2) · Prostatic Neoplasms (2) · Sarcoma (2) · Carcinoma, Non-Small-Cell Lung (1) · Glioblastoma (1) · Glioma (1) · Melanoma (1) · Multiple Myeloma (1) · Neoplasm Metastasis (1) · Neoplasms, Plasma Cell (1) · Neuroectodermal Tumors, Primitive (1) · Neuroendocrine Tumors (1) · Squamous Cell Carcinoma of Head and Neck (1)
ImmunoGenesis (4) · The University of Texas Health Science Center at San Antonio (2) · Threshold Pharmaceuticals (2) · Grupo Espanol de Tumores Neuroendocrinos (1) · Merck KGaA, Darmstadt, Germany (1) · University Health Network, Toronto (1)
United States (8) · Canada (2) · Japan (1) · Spain (1)
Mitesh Borad, MD (2) · Andrew Brenner, MD (1) · Andrew Brenner, MD, (1) · Enrique Grande, MD (1) · Jeffrey R Infante, MD (1) · Kristen Ganjoo, MD (1) · Shantan Reddy, MD (1) · Tillman Pearce, MD (1)
2014 (1)